C4 Therapeutics Inc
CCCC
Get informed when a big investor buys or sells
+ FollowMarket Cap$412.41M
Close$
$-3.19
178.1% downside
Current Fair Value
178.1% downsideOvervalued by 178.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $412.41 Million |
|---|---|
| Enterprise Value | $417.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.27 |
| Beta | 2.91 |
| Outstanding Shares | 126,074,555 |
Return
| Return on Equity | -41.02% |
|---|---|
| Return on Assets | -28.22% |
| Return on Invested Capital | -34.13% |
Valuation & Multiples
| P/E Ratio | -3.13 |
|---|---|
| PEG | 34.2 |
| Price to Sales | -4.08 |
| Price to Book Ratio | 4.08 |
| Enterprise Value to Revenue | -34.38 |
| Enterprise Value to EBIT | -3.93 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$7.67 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 19.56% |
|---|---|
| Total Calls | 300▼ 99.87% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.82%▼ 54.19% |
|---|---|
| Total Invested | $75.50M▼ 65.89% |
| Investors Holding | 39▼ 89.00% |
ESG Score
No data
About C4 Therapeutics Inc
99 employeesC4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and o...